BioPharm International-03-01-2006

Columns and Departments

March 01, 2006

A powerful film will have a hundred times the impact of a touchy-feely commercial.

Columns and Departments

March 01, 2006

In recent days, several different colleagues, in separate conversations about the industry, made remarkably similar comments.

Minimum disruption and maximum gain result when adopting a distributed process control and data management system for a cell culture and fermentation lab.

As part of its campaign to facilitate research on drugs and medical products, the Food and Drug Administration (FDA) recently issued new policies to encourage sponsors to conduct more informative and less costly early clinical trials. A new guidance on exploratory investigational drug applications (INDs) explains how scientists in industry and academia may test very small doses of a candidate compound to detect any pharmacologic effect before investing in more extensive in vitro and animal studies required for conventional phase 1 trials. The goal is to quickly identify products that show some promise of efficacy, and to halt research on those that fail to hit preliminary targets.

Articles

March 01, 2006

Australia's pharmaceutical industry as a whole turns over approximately US$10.7 billion a year and spends some US$384 million annually on research and development.

Signal-to-noise ratios are useful in robust engineering to design products and processes that consistently deliver on target.

The above statement reflects the opinion of a growing number of US governors and key state lawmakers.

Extra column effects must be accounted for to make a valid comparison

. . . Popular consortium meetings have focused on successful use of tools to drive improvement in cycle time reduction, deviation reduction, and improved production efficiency.